A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts

Medical Science Monitor

Volumn 18, Issue 9, 2012, Pages

  Lunder, Mojca ^a   Janić, Miodrag ^a   Žiberna, Lovro ^a   Drevenšek, Gorazd ^a   Šabovič, Mišo ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Atorvastatin; Cardiovascular prevention; Combination; Losartan; Low dose; Vasodilation

Indexed keywords

ATORVASTATIN; LACTATE DEHYDROGENASE; LOSARTAN POTASSIUM; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOTHELIUM; ENZYME RELEASE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; ISOLATED HEART; LOW DRUG DOSE; MALE; NONHUMAN; RAT; REPERFUSION INJURY; THORACIC AORTA; VASCULAR RING; VASODILATATION;

EID: 84866131690     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883347     Document Type: Article

References (34)

1. Jankowski P, Safar ME, Benetos A: Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system. Curr Pharm Des, 2009; 15: 571-84
2. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep, 2007; 59: 483-99
3. Kostapanos MS, Milionis HJ, Elisaf MS: An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther, 2008; 13: 157-74
4. Blum A, Shamburek R: The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis, 2008; 203: 325-30
5. Chalubinski M, Broncel M: Influence of statins on effector and regulatory immune mechanisms and their potential clinical relevance in treating autoimmune disorders. Med Sci Monit, 2010; 16(11): RA245-51
6. Renke M, Knap N, Tylicki L et al: Atorvastatin attenuates oxidative stress in patients with chronic kidney disease. Med Sci Monit, 2010; 16(3): LE3
7. Yu DQ, Lin SG, Chen JY et al: Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome. Arch Med Sci, 2011; 7: 433-39
8. Ridker PM, Danielson E, Rifai N, Glynn RJ: Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension, 2006; 48: 73-79
9. Schieffer B, Bunte C, Witte J et al: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol, 2004; 44: 362-68
10. Landmesser U, Drexler H: Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl, 2006; 24: S39-43
11. Lunder M, Janic M, Sabovic M: Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Cardiovasc Prev Rehabil; 2011; [Epub ahead of print]
12. Lunder M, Janic M, Habjan S, Sabovic M: Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males a pilot study. Atherosclerosis, 2011; 215: 446-51
13. Katsumoto M, Shingu T, Kuwashima R et al: Biphasic effect of HMGCoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J, 2005; 69: 1547-55
14. Matsatoshi F, Morimoto T, Ikemoto M et al: Dose-dependency in pleiotropic effects of atorvastatin. Int J Angiol, 2007; 16: 89-91
15. Wroblewski F, Ladue JS: Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med, 1955; 90: 210-13
16. Kuhar P, Lunder M, Drevensek G: The role of gender and sex hormones in ischemic-reperfusion injury in isolated rat hearts. Eur J Pharmacol, 2007; 561: 151-59
17. Ziberna L, Lunder M, Kuzner J, Drevensek G: Normothermic and hypothermic models for studying the deleterious effects of hypoxia-reoxygenation on EDHF-mediated relaxation in isolated porcine coronary arteries. J Pharmacol Toxicol Methods, 2009; 59: 1-6
18. Calkin AC, Giunti S, Sheehy KJ et al: The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia, 2008; 51: 1731-40
19. Grothusen C, Bley S, Selle T et al: Combined effects of HMG-CoAreductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis, 2005; 182: 57-69
20. Jones SP, Gibson MF, Rimmer DM III et al: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol, 2002; 40: 1172-78
21. Yi I, Lee JJ, Park JS et al: Enhanced effect of losartan and rosuvastatin on neointima hyperplasia. Arch Pharm Res, 2010; 33: 593-600
22. Horiuchi M, Cui TX, Li Z et al: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation, 2003; 107: 106-12
23. Sohma R, Inoue T, Abe S et al: Cardioprotective effects of low-dose combination therapy with a statin and an angiotensin receptor blocker in a rat myocardial infarction model. J Cardiol, 2012; 59: 91-96
24. Yamamoto E, Yamashita T, Tanaka T et al: Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol, 2007; 27: 556-63
25. Liu L, Zhao SP, Zhou HN et al: Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol, 2007; 50: 50-55
26. Hussein O, Shneider J, Rosenblat M, Aviram M: Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against lowdensity lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol, 2002; 40: 28-34
27. Lunder M, Janic M, Jug B, Sabovic M: The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial. Eur J Intern Med, 2012; 23(3): 261-66
28. Koh KK, Han SH, Oh PC et al: Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis, 2010; 209: 307-13
29. Blum A, Shamburek R: The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis, 2009; 203: 325-30
30. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res, 2000; 47: 648-57
31. Maczewski M, Maczewska J, Duda M: Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors. Br J Pharmacol, 2008; 154: 1640-48
32. Castejon AM, Zollner E, Tristano AG, Cubeddu LX: Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells. J Cardiovasc Pharmacol, 2007; 50: 708-11
33. Weerateerangkul P, Chattipakorn S, Chattipakorn N: Roles of the nitric oxide signaling pathway in cardiac ischemic preconditioning against myocardial ischemia-reperfusion injury. Med Sci Monit, 2011; 17(2): RA44-52
34. Stefano GB, Esch T, Bilfinger TV, Kream RM: Proinflammation and preconditioning protection are part of a common nitric oxide mediated process. Med Sci Monit, 2010; 16(6): RA125-30